# A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

> **NCT01047579** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rivastigmine transdermal

## Key facts

- **NCT ID:** NCT01047579
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047579, "A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01047579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*